CMS announces drugs selected for third round of drug price negotiations
The Centers for Medicare & Medicaid Services Jan. 27 announced 15 drugs under Medicare Parts D and B selected for the third round of price negotiations. Negotiations will occur this year and any resulting prices will become effective in 2028. CMS said the selected drugs accounted for nearly $27 billion, or nearly 6%, in total prescription drug spending under Parts D and B between November 2024 and October 2025. Additionally, CMS released a list of the top 50 negotiation-eligible drugs based on combined expenditures under Parts D and B.
Related News Articles
Headline
The Department of Health and Human Services Office of Inspector General Jan. 27 released a bulletin addressing how direct-to-consumer drug programs can sell…
Headline
The White House released a health care plan Jan. 15 addressing drug prices, health insurance premiums and price transparency efforts. The plan includes…
Headline
The Department of Health and Human Services and Drug Enforcement Administration Dec. 30 released a temporary rule extending for the fourth time waiver…
Headline
The Centers for Medicare & Medicaid Services Dec. 23 introduced a new drug pricing model for Medicare Part D and Medicaid beneficiaries. The Better…
Headline
The Centers for Medicare & Medicaid Services Dec. 19 issued two proposed rules for implementing alternative drug pricing models. The first proposed…
Headline
The White House announced Dec. 19 that it reached most-favored-nation deals with nine pharmaceutical companies, aligning their drug prices with the lowest paid…